-
Citizens JMP Reiterates Market Perform Rating on Intellia Therapeutics (NTLA)
-
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
-
Citizens JMP Reiterates Market Perform Rating on Intellia Therapeutics (NTLA)
-
Citizens JMP Reiterates Market Perform Rating on Intellia Therapeutics (NTLA)
-
Intellia Therapeutics (NTLA) PT Raised to $14 at Citi
-
Citi Reiterates Neutral Rating on Intellia Therapeutics (NTLA)
-
Intellia Therapeutics (NTLA) PT Lowered to $29 at Citi
-
Citi on Intellia Therapeutics (NTLA): 'we believe that NTLA-2001 might find its home as a niche offering'
-
Intellia Therapeutics (NTLA) Mentioned Positively at Citi, 'We expect shares to open higher Wednesday'
-
Pre-Open Stock Movers 06/28: (NTLA) (AVXL) (EDIT) Higher; (GTEC) (XPO) (CCL) Lower (more...)
-
Pre-Open Stock Movers 06/02: (MGI) (WU) (SWBI) Higher; (PUMP) (INVH) (GH) Lower (more...)
-
After-Hours Stock Movers 6/1: (MGI) (KLDO) (XGN) HIGHER; (PUMP) (INVH) (GH) LOWER (more...)
-
Intellia Therapeutics to Present at September Healthcare Investor Conferences

